Pfizer’s Vaccines, Oncology and Consumer Healthcare businesses are integral to the company’s innovative core and growth strategy. Pfizer Vaccines includes Prevnar13, the world’s leading pneumococcal vaccine, and a promising pipeline of preventative and therapeutic vaccines. Pfizer Oncology is improving the standard of care for cancer patients with products such as Sutent, Xalkori and Inlyta; its extensive pipeline includes late-stage molecules to treat advanced breast cancer and non-small cell lung cancer. Pfizer Consumer Healthcare is among the largest over-the-counter (OTC) health care product businesses in the world and markets two of the top 10 global consumer brands – Advil and Centrum.
Albert has more than twenty years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current position, he was President and General Manager of Pfizer’s Established Products Business Unit, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio (including legacy brands and generics).
Albert joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University.